Name | No. | For Patients with | Purpose |
---|---|---|---|
SIOP EPENDYMOMA II | 2013-002766-39 | Children, adolescents and young adults with ependymoma |
Test |
DSSG Group: Paediatric
NBL NK Study (TCD)
Name | No. | For Patients with | Purpose |
---|---|---|---|
NBL NK Study (TCD) | Neuroblastoma |
Targeting metabolism to improve NK cell mediated Immunotherapy for the treatment of Neuroblastoma |
MONTE Biomarker Study (RCSI)
Name | No. | For Patients with | Purpose |
---|---|---|---|
MONTE Biomarker Study (RCSI) | 19-04 | High Risk Neuroblastoma |
Modulation of drug resistance in high risk neurobalstoma through exosomes. |
PHITT
Name | No. | For Patients with | Purpose |
---|---|---|---|
PHITT | 18-17 | Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). |
The trial will evaluate whether reducing treatment for low risk Hepatoblastoma (HB) patients maintains their excellent event free survival (EFS) and decreases acute and long-term toxicity. |
LOXO TRK 15003
Name | No. | For Patients with | Purpose |
---|---|---|---|
LOXO TRK 15003 | 18-36 | Paediatric advance solid or primary CNS tumours. |
To determine the safety of oral LOXO-101 (larotrectinib) and to determine the overall response rate. |